NO323780B1 - Nye krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, fremgangsmate for fremstilling og anvendelser av slike samt farmasoytisk preparat inneholdende nevnte nye forbindelser. - Google Patents

Nye krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, fremgangsmate for fremstilling og anvendelser av slike samt farmasoytisk preparat inneholdende nevnte nye forbindelser. Download PDF

Info

Publication number: NO323780B1
Authority: NO; Norway
Prior art keywords: compound; formula; mixture; water; solvent
Prior art date: 2000-06-02

Application number

NO20025756A

Other languages

English (en)

Norwegian (no)

Other versions

NO20025756D0 (no

NO20025756L (no

Inventor

Martin Bohlin

Steve Cosgrove

Bo Lassen

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-02

Filing date

2002-11-29

Publication date

2007-07-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9892841&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO323780(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-11-29 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2002-11-29 Publication of NO20025756D0 publication Critical patent/NO20025756D0/no

2003-01-24 Publication of NO20025756L publication Critical patent/NO20025756L/no

2007-07-02 Publication of NO323780B1 publication Critical patent/NO323780B1/no

Links

150000001875 compounds Chemical class 0.000 title claims description 116
238000000034 method Methods 0.000 title claims description 50
230000008569 process Effects 0.000 title claims description 10
-1 pyrimidine compound Chemical class 0.000 title claims description 5
239000008194 pharmaceutical composition Substances 0.000 title claims description 3
238000002360 preparation method Methods 0.000 title description 12
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 63
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
239000000203 mixture Substances 0.000 claims description 35
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 33
238000000634 powder X-ray diffraction Methods 0.000 claims description 24
239000002904 solvent Substances 0.000 claims description 24
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 16
230000008018 melting Effects 0.000 claims description 14
238000002844 melting Methods 0.000 claims description 14
238000004519 manufacturing process Methods 0.000 claims description 13
239000003814 drug Substances 0.000 claims description 12
230000001732 thrombotic effect Effects 0.000 claims description 11
239000000825 pharmaceutical preparation Substances 0.000 claims description 7
230000002265 prevention Effects 0.000 claims description 6
208000018262 Peripheral vascular disease Diseases 0.000 claims description 5
NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 claims description 4
239000002671 adjuvant Substances 0.000 claims description 4
208000026106 cerebrovascular disease Diseases 0.000 claims description 4
208000029078 coronary artery disease Diseases 0.000 claims description 4
210000004351 coronary vessel Anatomy 0.000 claims description 4
JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 claims description 4
206010028980 Neoplasm Diseases 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
229960004592 isopropanol Drugs 0.000 claims description 3
150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 2
125000005233 alkylalcohol group Chemical group 0.000 claims description 2
150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 2
150000001983 dialkylethers Chemical class 0.000 claims description 2
150000002576 ketones Chemical class 0.000 claims description 2
238000001938 differential scanning calorimetry curve Methods 0.000 claims 3
125000003158 alcohol group Chemical group 0.000 claims 1
239000000243 solution Substances 0.000 description 33
238000002425 crystallisation Methods 0.000 description 14
230000008025 crystallization Effects 0.000 description 13
238000001819 mass spectrum Methods 0.000 description 12
239000013078 crystal Substances 0.000 description 10
239000003480 eluent Substances 0.000 description 9
239000000126 substance Substances 0.000 description 9
AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 8
239000000463 material Substances 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
238000002441 X-ray diffraction Methods 0.000 description 7
238000000113 differential scanning calorimetry Methods 0.000 description 7
229940079593 drug Drugs 0.000 description 7
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
239000000843 powder Substances 0.000 description 7
239000000725 suspension Substances 0.000 description 7
239000003826 tablet Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
238000009472 formulation Methods 0.000 description 5
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 4
238000010899 nucleation Methods 0.000 description 4
239000007787 solid Substances 0.000 description 4
238000001228 spectrum Methods 0.000 description 4
XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229910004298 SiO 2 Inorganic materials 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
239000008187 granular material Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000007858 starting material Substances 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
238000011282 treatment Methods 0.000 description 3
230000002792 vascular Effects 0.000 description 3
WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
206010002388 Angina unstable Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
108091007262 P2T receptors Proteins 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
208000007814 Unstable Angina Diseases 0.000 description 2
206010047249 Venous thrombosis Diseases 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
238000002399 angioplasty Methods 0.000 description 2
239000012296 anti-solvent Substances 0.000 description 2
238000010533 azeotropic distillation Methods 0.000 description 2
DIKBFYAXUHHXCS-UHFFFAOYSA-N bromoform Chemical compound BrC(Br)Br DIKBFYAXUHHXCS-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
230000008859 change Effects 0.000 description 2
229940112141 dry powder inhaler Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000012535 impurity Substances 0.000 description 2
208000014674 injury Diseases 0.000 description 2
201000004332 intermediate coronary syndrome Diseases 0.000 description 2
OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000006911 nucleation Effects 0.000 description 2
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
230000010118 platelet activation Effects 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000002537 thrombolytic effect Effects 0.000 description 2
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
VNSQXWISTNFYFV-UHFFFAOYSA-N 1,3-dioxol-4-ol Chemical compound OC1=COCO1 VNSQXWISTNFYFV-UHFFFAOYSA-N 0.000 description 1
RZWHKKIXMPLQEM-UHFFFAOYSA-N 1-chloropropan-1-ol Chemical compound CCC(O)Cl RZWHKKIXMPLQEM-UHFFFAOYSA-N 0.000 description 1
GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical class N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 description 1
DDEDQHVHVPJFAC-UHFFFAOYSA-N 4,6-dichloro-5-nitro-2-propylsulfanylpyrimidine Chemical compound CCCSC1=NC(Cl)=C([N+]([O-])=O)C(Cl)=N1 DDEDQHVHVPJFAC-UHFFFAOYSA-N 0.000 description 1
KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
229920000945 Amylopectin Polymers 0.000 description 1
208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
206010003178 Arterial thrombosis Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
206010014498 Embolic stroke Diseases 0.000 description 1
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 1
206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000014767 Myeloproliferative disease Diseases 0.000 description 1
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
208000012322 Raynaud phenomenon Diseases 0.000 description 1
206010038563 Reocclusion Diseases 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
206010040621 Shunt occlusion Diseases 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
208000005485 Thrombocytosis Diseases 0.000 description 1
206010043647 Thrombotic Stroke Diseases 0.000 description 1
201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
208000032109 Transient ischaemic attack Diseases 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
208000012346 Venoocclusive disease Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
206010003230 arteritis Diseases 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
229950005228 bromoform Drugs 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
BUZRUIZTMOKRPB-UHFFFAOYSA-N carboxycarbamic acid Chemical compound OC(=O)NC(O)=O BUZRUIZTMOKRPB-UHFFFAOYSA-N 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
VCVOSERVUCJNPR-UHFFFAOYSA-N cyclopentane-1,2-diol Chemical compound OC1CCCC1O VCVOSERVUCJNPR-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000010908 decantation Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
238000013171 endarterectomy Methods 0.000 description 1
FDLDWKIEWAWOSL-UHFFFAOYSA-N ethyl acetate;2-methylpentane Chemical compound CCCC(C)C.CCOC(C)=O FDLDWKIEWAWOSL-UHFFFAOYSA-N 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002618 extracorporeal membrane oxygenation Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
YCOZIPAWZNQLMR-UHFFFAOYSA-N heptane - octane Natural products CCCCCCCCCCCCCCC YCOZIPAWZNQLMR-UHFFFAOYSA-N 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000010410 layer Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000012907 medicinal substance Substances 0.000 description 1
239000000155 melt Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
PPYPHCLFWPCGAU-UHFFFAOYSA-N methyl 2-(trifluoromethylsulfonyloxy)acetate Chemical compound COC(=O)COS(=O)(=O)C(F)(F)F PPYPHCLFWPCGAU-UHFFFAOYSA-N 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229910000489 osmium tetroxide Inorganic materials 0.000 description 1
239000012285 osmium tetroxide Substances 0.000 description 1
229940019331 other antithrombotic agent in atc Drugs 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
238000002616 plasmapheresis Methods 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
201000011461 pre-eclampsia Diseases 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
238000004321 preservation Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
238000002278 reconstructive surgery Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
208000013223 septicemia Diseases 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000001476 sodium potassium tartrate Substances 0.000 description 1
235000011006 sodium potassium tartrate Nutrition 0.000 description 1
238000000935 solvent evaporation Methods 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000005496 tempering Methods 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
239000003634 thrombocyte concentrate Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
201000010875 transient cerebral ischemia Diseases 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
230000003966 vascular damage Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Neurology (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO20025756A 2000-06-02 2002-11-29 Nye krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, fremgangsmate for fremstilling og anvendelser av slike samt farmasoytisk preparat inneholdende nevnte nye forbindelser. NO323780B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0013407.2A GB0013407D0 (en)	2000-06-02	2000-06-02	Forms of a chemical compound
PCT/SE2001/001239 WO2001092262A1 (fr)	2000-06-02	2001-05-31	Nouvelle forme cristalline et amorphe d'un compose de triazolo(4,5-d)pyrimidine

Publications (3)

Publication Number	Publication Date
NO20025756D0 NO20025756D0 (no)	2002-11-29
NO20025756L NO20025756L (no)	2003-01-24
NO323780B1 true NO323780B1 (no)	2007-07-02

Family

ID=9892841

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO20025756A NO323780B1 (no)	2000-06-02	2002-11-29	Nye krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, fremgangsmate for fremstilling og anvendelser av slike samt farmasoytisk preparat inneholdende nevnte nye forbindelser.
NO20071547A NO332306B1 (no)	2000-06-02	2007-03-23	Nye krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytisk sammensetning
NO20120595A NO333289B1 (no)	2000-06-02	2012-05-14	Blanding av vesentlig krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, farmasoytisk sammensetning samt anvendelser derav

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
NO20071547A NO332306B1 (no)	2000-06-02	2007-03-23	Nye krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytisk sammensetning
NO20120595A NO333289B1 (no)	2000-06-02	2012-05-14	Blanding av vesentlig krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, farmasoytisk sammensetning samt anvendelser derav

Country Status (36)

Country	Link
US (3)	US20030181469A1 (fr)
EP (3)	EP2292622A1 (fr)
JP (3)	JP5036947B2 (fr)
KR (1)	KR100781864B1 (fr)
CN (2)	CN1817883B (fr)
AR (2)	AR032335A1 (fr)
AT (2)	ATE320430T1 (fr)
AU (4)	AU2001262874B2 (fr)
BG (3)	BG65837B1 (fr)
BR (1)	BR0111328A (fr)
CA (1)	CA2408596C (fr)
CY (1)	CY1113047T1 (fr)
CZ (2)	CZ304347B6 (fr)
DE (1)	DE60117972T2 (fr)
DK (2)	DK1493745T3 (fr)
EE (1)	EE05222B1 (fr)
ES (2)	ES2384708T3 (fr)
GB (1)	GB0013407D0 (fr)
HK (2)	HK1052347B (fr)
HU (2)	HU229374B1 (fr)
IL (4)	IL152777A0 (fr)
IS (2)	IS2609B (fr)
MX (1)	MXPA02011795A (fr)
MY (2)	MY148652A (fr)
NO (3)	NO323780B1 (fr)
NZ (1)	NZ522638A (fr)
PH (1)	PH12011000127A1 (fr)
PL (2)	PL359172A1 (fr)
PT (2)	PT1493745E (fr)
RU (3)	RU2325391C2 (fr)
SG (1)	SG135965A1 (fr)
SI (2)	SI1493745T1 (fr)
SK (1)	SK287817B6 (fr)
UA (1)	UA73181C2 (fr)
WO (1)	WO2001092262A1 (fr)
ZA (1)	ZA200209324B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI229674B (en)	1998-12-04	2005-03-21	Astra Pharma Prod	Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013407D0 (en)	2000-06-02	2000-07-26	Astrazeneca Ab	Forms of a chemical compound
GB0013488D0 (en) *	2000-06-02	2000-07-26	Astrazeneca Ab	Chemical compound
JP4298212B2 (ja) *	2002-03-29	2009-07-15	大日本印刷株式会社	塩酸エピナスチン高融点型結晶の製造法
WO2008024044A1 (fr) *	2006-08-21	2008-02-28	Astrazeneca Ab	Compositions pour administration orale comprenant un dérivé de triazolo [4, 5] pyrimidine
TWI482772B (zh) *	2006-08-21	2015-05-01	Astrazeneca Ab	適合口服且包含***并[4,5-d]嘧啶衍生物之組合物
US7566722B2 (en) *	2006-10-31	2009-07-28	Janssen Pharmaceutica, N.V.	Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists
CN103071154A (zh) *	2007-04-13	2013-05-01	千年药品公司	用起因子xa抑制剂作用的化合物的组合抗凝治疗
TWI496776B (zh) *	2007-11-15	2015-08-21	Astrazeneca Ab	製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法
UA100864C2 (uk) *	2007-12-03	2013-02-11	Астразенека Аб	Спосіб лікування або запобігання аневризмі черевної аорти
MX2011002505A (es)	2008-09-09	2011-04-07	Astrazeneca Ab	Un proceso para preparar [1s-[1-alfa, 2-alfa, 3-beta (1s, 2r) 5-beta] ] -3-[7-[2-(3,4-difluorofenil)-ciclopropilamino]-5-(propil tio) 3h-1, 2, 3-triazolo [4,5-d] pirimidin-3-il] -5-(2-hidroxietoxi) ciclopentan-1, 2-diol y sus intermediarios.
EP2459564B1 (fr)	2009-07-27	2016-09-07	Auspex Pharmaceuticals, Inc.	Modulateurs cyclopropylés du récepteur p2y12
JP2013512886A (ja) *	2009-12-03	2013-04-18	アストラゼネカアクチボラグ	血小板の凝集阻害剤トリアゾロ［４，５−ｄ］ピリミジン共結晶
EP2515871B1 (fr)	2009-12-23	2015-09-23	ratiopharm GmbH	Forme de dosage solide pharmaceutique de ticagrlor
CZ2011229A3 (cs) *	2011-04-19	2012-08-15	Zentiva, K.S.	Opticky aktivní soli (3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyklopenta-[d][1,3]dioxol-4-olu a zpusob jejich prípravy
CA2836394A1 (fr)	2011-06-01	2012-12-06	Astrazeneca Ab	Nouveaux co-cristaux de ticagrelor
EP2785716A1 (fr) *	2011-11-30	2014-10-08	Actavis Group PTC EHF	Nouvelle forme cristalline du ticagrelor et procédé pour sa préparation
WO2013150495A2 (fr)	2012-04-05	2013-10-10	Dr. Reddy's Laboratories Limited	Préparation de ticagrelor
BR112014032085A2 (pt)	2012-06-29	2017-06-27	Zentiva Ks	solvato de ticagrelor, processos para a preparação de um solvato e para a preparação de um cocristal, cocristal de ticagrelor, e, usos de um solvato e de um cocristal
US9284320B2 (en)	2012-07-04	2016-03-15	Lek Pharmaceuticals D.D.	Ticagrelor adducts with divalent metal salts
CZ2012705A3 (cs) *	2012-10-16	2014-04-23	Zentiva, K.S.	Pevná orální farmaceutická formulace obsahující ticagrelor
CN103772393B (zh) *	2012-10-18	2017-08-04	博瑞生物医药（苏州）股份有限公司	替卡格雷的晶型及其制备方法
WO2014083139A1 (fr) *	2012-11-29	2014-06-05	Actavis Group Ptc Ehf	Nouvelle forme amorphe de ticagrelor
CN103848836B (zh) *	2012-12-07	2016-08-03	天津市汉康医药生物技术有限公司	替卡格雷倍半水合物及其制备方法
WO2014118808A2 (fr) *	2013-02-04	2014-08-07	Hetero Research Foundation	Dispersion solide de ticagrelor
CZ307217B6 (cs)	2013-03-14	2018-04-04	Zentiva, K.S.	Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru
IN2013MU01111A (fr) *	2013-03-25	2015-05-01	Glenmark Generics Ltd
CN104098570A (zh) *	2013-04-07	2014-10-15	杭州领业医药科技有限公司	替卡格雷晶型及其制备方法和用途
CN104098572A (zh) *	2013-04-08	2014-10-15	博瑞生物医药技术(苏州)有限公司	替卡格雷共晶型
CN107573333B (zh) *	2013-04-10	2019-10-18	江苏恒瑞医药股份有限公司	替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
EP2813216A1 (fr)	2013-06-10	2014-12-17	Zentiva, a.s.	Ticagrelor amorphe stabilisé
WO2014170026A1 (fr)	2013-04-18	2014-10-23	Zentiva, K.S.	Ticagrelor amorphe stabilisé
EP3003276A1 (fr)	2013-05-29	2016-04-13	ratiopharm GmbH	Forme posologique pharmaceutique solide
CN106496235A (zh) *	2013-06-03	2017-03-15	杭州领业医药科技有限公司	结晶形态的***[4,5‑d]嘧啶化合物及其制备方法和用途
EP3004113A2 (fr) *	2013-06-04	2016-04-13	Dr. Reddy's Laboratories Ltd.	Préparation de ticagrélor
EP2816043A1 (fr)	2013-06-21	2014-12-24	LEK Pharmaceuticals d.d.	Particules Ticagrelor sphériques
WO2015001489A1 (fr) *	2013-07-01	2015-01-08	Ranbaxy Laboratories Limited	Compositions pharmaceutiques de ticagrélor
CN104341423B (zh) *	2013-08-02	2017-03-01	上海京新生物医药有限公司	替格瑞洛的一水合物及其制备方法与在制药中的应用
CN104370912A (zh) *	2013-08-13	2015-02-25	开原亨泰制药股份有限公司	替卡格雷多晶型体及其制备方法
WO2015037016A2 (fr) *	2013-09-10	2015-03-19	Laurus Labs Private Limited	Procédé amélioré de préparation de ticagrelor et d'intermédiaires de celui-ci
CZ2013866A3 (cs)	2013-11-08	2015-05-20	Zentiva, K.S.	Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
CN104650085A (zh) *	2013-11-22	2015-05-27	天津市汉康医药生物技术有限公司	替卡格雷倍半水合物化合物
CN103601726B (zh) *	2013-12-02	2016-09-28	浙江大学	两种替格瑞洛药物共晶及其制备方法
CN104710425B (zh) *	2013-12-16	2019-06-14	石药集团中奇制药技术（石家庄）有限公司	一种替格瑞洛新结晶及其制备方法
CN104650091B (zh) *	2014-01-24	2016-10-05	福州乾正药业有限公司	替格瑞洛的微粉化及其晶型，以及制备方法和药物应用
CN104940204A (zh) *	2014-03-27	2015-09-30	广东东阳光药业有限公司	一种替格瑞洛固体制剂及其制备方法
WO2015162537A1 (fr) *	2014-04-23	2015-10-29	Glenmark Pharmaceuticals Limited; Glenmark Generics Limited	Procédé de préparation de ticagrélor
WO2015162630A1 (fr)	2014-04-25	2015-10-29	Anlon Chemical Research Organization	Nouveaux procédés de préparation de triazolo[4,5-d]-pyrimidines, dont le ticagrelor, via de nouveaux intermédiaires et une nouvelle voie de synthèse
CN105315282B (zh) *	2014-07-15	2018-09-21	博瑞生物医药（苏州）股份有限公司	一种制备替卡格雷无定型的方法
WO2016016907A1 (fr) *	2014-08-01	2016-02-04	Msn Laboratories Private Limited	Nouveaux polymorphes de (1s,2s,3r,5s)-3-[7-{[(1r,2s)-2-(3,4-difluorophényl)cyclopropyl]amino}-5-(propylthio)-3h-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyéthoxy)cyclopentane-1,2-diol
US10017515B2 (en)	2014-08-11	2018-07-10	Sun Pharmaceutical Industries Limited	Stable amorphous ticagrelor and a process for its preparation
CN104193747B (zh) *	2014-08-12	2016-05-11	许彩霞	替卡格雷无定形的制备
WO2016116942A1 (fr)	2015-01-20	2016-07-28	Anlon Chemical Research Organization	Nouveaux composés pharmaceutiques comprenant du ticagrélor avec des sels d'aspirine
CN105968113B (zh) *	2015-03-12	2019-06-07	四川海思科制药有限公司	一种***并嘧啶衍生物及其应用
WO2017072790A1 (fr) *	2015-10-26	2017-05-04	Avra Laboratories Pvt. Ltd.	Procédé amélioré pour la synthèse de ticagrelor
WO2017118633A1 (fr) *	2016-01-05	2017-07-13	Amneal Pharmaceuticals Company Gmbh	Forme cristalline de ticagrelor
CN107595789B (zh)	2016-04-21	2021-01-15	阿斯利康(瑞典)有限公司	口腔崩解片
US10905691B2 (en)	2016-09-09	2021-02-02	Université de Liège	Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection
DK3292867T3 (da) *	2016-09-09	2019-07-22	Univ Liege	Ny brug af triazol(4,5-d)pyrimidinderivater til brug i forebyggelsen og behandlingen af bakteriel infektion
KR101916956B1 (ko)	2016-12-13	2018-11-08	보령제약 주식회사	티카그렐러의 신규한 고체 형태 및 이의 제조방법
WO2018178997A1 (fr)	2017-03-31	2018-10-04	Natco Pharma Limited	Nouvelle forme cristalline du ticagrelor
WO2019127294A1 (fr) *	2017-12-29	2019-07-04	浙江天宇药业股份有限公司	Procédé de purification de ticagrelor
EP3761965A1 (fr)	2018-03-08	2021-01-13	Pharmaceutical Oriented Services Ltd	Formulation de comprimé contenant du ticagrelor
EA202190328A1 (ru)	2018-07-27	2021-07-01	КРКА, д.д., НОВО МЕСТО	Фармацевтическая композиция, содержащая тикагрелор
CN110194771A (zh) *	2019-05-08	2019-09-03	北京济美堂医药研究有限公司	一种替格瑞洛药用ii晶型的制备方法
CN114634489B (zh) *	2022-04-19	2023-07-04	奎马特里克斯有限公司	结晶形式

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5561134A (en) *	1990-09-25	1996-10-01	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
PL182680B1 (pl) *	1995-07-11	2002-02-28	Astrazeneca Ab	Nowe inhibitory skupiania się płytek krwi
ATE213245T1 (de) *	1996-12-20	2002-02-15		Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente
TW530058B (en)	1997-07-22	2003-05-01	Astra Pharma Prod	Triazolo [4,5-d]pyrimidine compounos and their use and process for preparation
WO1999005150A1 (fr) *	1997-07-25	1999-02-04	Gilead Sciences, Inc.	Composition d'analogues de nucleotides et procede de synthese
TWI229674B (en) *	1998-12-04	2005-03-21	Astra Pharma Prod	Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904129D0 (sv) *	1999-11-15	1999-11-15	Astra Pharma Prod	Novel compounds
GB0013488D0 (en) *	2000-06-02	2000-07-26	Astrazeneca Ab	Chemical compound
GB0013407D0 (en)	2000-06-02	2000-07-26	Astrazeneca Ab	Forms of a chemical compound

2000
- 2000-06-02 GB GBGB0013407.2A patent/GB0013407D0/en not_active Ceased
2001
- 2001-05-22 AR ARP010102432A patent/AR032335A1/es unknown
- 2001-05-31 SG SG200500599-6A patent/SG135965A1/en unknown
- 2001-05-31 PL PL01359172A patent/PL359172A1/xx not_active IP Right Cessation
- 2001-05-31 SI SI200131013T patent/SI1493745T1/sl unknown
- 2001-05-31 EP EP10182133A patent/EP2292622A1/fr not_active Withdrawn
- 2001-05-31 HU HU0302284A patent/HU229374B1/hu unknown
- 2001-05-31 AT AT01937109T patent/ATE320430T1/de active
- 2001-05-31 JP JP2002500875A patent/JP5036947B2/ja not_active Expired - Lifetime
- 2001-05-31 BR BR0111328-3A patent/BR0111328A/pt not_active Application Discontinuation
- 2001-05-31 NZ NZ522638A patent/NZ522638A/en not_active IP Right Cessation
- 2001-05-31 AU AU2001262874A patent/AU2001262874B2/en not_active Expired
- 2001-05-31 PT PT04015299T patent/PT1493745E/pt unknown
- 2001-05-31 UA UA20021210808A patent/UA73181C2/uk unknown
- 2001-05-31 AU AU6287401A patent/AU6287401A/xx active Pending
- 2001-05-31 MY MYPI20092026A patent/MY148652A/en unknown
- 2001-05-31 ES ES04015299T patent/ES2384708T3/es not_active Expired - Lifetime
- 2001-05-31 RU RU2002135589/04A patent/RU2325391C2/ru active
- 2001-05-31 PL PL392882A patent/PL392882A1/pl not_active Application Discontinuation
- 2001-05-31 MX MXPA02011795A patent/MXPA02011795A/es active IP Right Grant
- 2001-05-31 SK SK1685-2002A patent/SK287817B6/sk not_active IP Right Cessation
- 2001-05-31 PT PT01937109T patent/PT1289992E/pt unknown
- 2001-05-31 CN CN2006100025095A patent/CN1817883B/zh not_active Expired - Lifetime
- 2001-05-31 EE EEP200200665A patent/EE05222B1/xx unknown
- 2001-05-31 IL IL15277701A patent/IL152777A0/xx unknown
- 2001-05-31 DE DE60117972T patent/DE60117972T2/de not_active Expired - Lifetime
- 2001-05-31 MY MYPI20012578A patent/MY140674A/en unknown
- 2001-05-31 US US10/296,990 patent/US20030181469A1/en not_active Abandoned
- 2001-05-31 EP EP04015299.3A patent/EP1493745B2/fr not_active Expired - Lifetime
- 2001-05-31 DK DK04015299.3T patent/DK1493745T3/da active
- 2001-05-31 CN CNB018105823A patent/CN1247583C/zh not_active Expired - Lifetime
- 2001-05-31 EP EP01937109A patent/EP1289992B1/fr not_active Expired - Lifetime
- 2001-05-31 CZ CZ2002-3918A patent/CZ304347B6/cs not_active IP Right Cessation
- 2001-05-31 HU HU1300386A patent/HU230471B1/hu unknown
- 2001-05-31 CA CA2408596A patent/CA2408596C/fr not_active Expired - Lifetime
- 2001-05-31 KR KR1020027016379A patent/KR100781864B1/ko active IP Right Review Request
- 2001-05-31 SI SI200130541T patent/SI1289992T1/sl unknown
- 2001-05-31 ES ES01937109T patent/ES2259031T3/es not_active Expired - Lifetime
- 2001-05-31 CZ CZ2012-293A patent/CZ307468B6/cs not_active IP Right Cessation
- 2001-05-31 AT AT04015299T patent/ATE555115T1/de active
- 2001-05-31 WO PCT/SE2001/001239 patent/WO2001092262A1/fr active Application Filing
- 2001-05-31 DK DK01937109T patent/DK1289992T3/da active
2002
- 2002-11-11 IL IL152777A patent/IL152777A/en active IP Right Grant
- 2002-11-15 IS IS6623A patent/IS2609B/is unknown
- 2002-11-15 ZA ZA200209324A patent/ZA200209324B/en unknown
- 2002-11-28 BG BG107331A patent/BG65837B1/bg unknown
- 2002-11-29 NO NO20025756A patent/NO323780B1/no not_active IP Right Cessation
2003
- 2003-06-24 HK HK03104536.0A patent/HK1052347B/zh not_active IP Right Cessation
2005
- 2005-06-16 HK HK05105060.9A patent/HK1073101A1/xx not_active IP Right Cessation
- 2005-08-30 RU RU2005127356/04A patent/RU2418802C2/ru active Protection Beyond IP Right Term
- 2005-10-03 US US11/240,801 patent/US7265124B2/en not_active Expired - Lifetime
2007
- 2007-03-05 AU AU2007200958A patent/AU2007200958B2/en active Active
- 2007-03-23 NO NO20071547A patent/NO332306B1/no not_active IP Right Cessation
- 2007-08-24 US US11/892,597 patent/US20070293513A1/en not_active Abandoned
- 2007-11-19 IL IL187482A patent/IL187482A/en active IP Right Grant
2008
- 2008-07-24 AR ARP080103205A patent/AR068086A2/es unknown
2009
- 2009-06-02 IS IS8825A patent/IS3019B/is unknown
- 2009-08-12 BG BG10110440A patent/BG66332B1/bg unknown
- 2009-12-07 IL IL202582A patent/IL202582A/en active IP Right Grant
2010
- 2010-12-10 RU RU2010150799/04A patent/RU2010150799A/ru not_active Application Discontinuation
- 2010-12-24 AU AU2010257449A patent/AU2010257449B2/en not_active Expired
2011
- 2011-04-19 PH PH12011000127A patent/PH12011000127A1/en unknown
- 2011-08-18 BG BG10111017A patent/BG111017A/bg unknown
2012
- 2012-05-01 JP JP2012104575A patent/JP5684192B2/ja not_active Expired - Lifetime
- 2012-05-14 NO NO20120595A patent/NO333289B1/no not_active IP Right Cessation
- 2012-06-21 CY CY20121100559T patent/CY1113047T1/el unknown
2014
- 2014-04-07 JP JP2014078665A patent/JP2014129423A/ja active Pending

Also Published As

Publication number	Publication date
AR032335A1 (es)	2003-11-05
DE60117972T2 (de)	2006-11-23
AU2007200958A1 (en)	2007-03-29
CA2408596A1 (fr)	2001-12-06
NZ522638A (en)	2004-06-25
IL202582A (en)	2012-12-31
US7265124B2 (en)	2007-09-04
WO2001092262A1 (fr)	2001-12-06
US20070173518A1 (en)	2007-07-26
RU2325391C2 (ru)	2008-05-27
EP1493745B1 (fr)	2012-04-25
IS8825A (is)	2009-06-02
EP1289992B1 (fr)	2006-03-15
NO333289B1 (no)	2013-04-29
CZ304347B6 (cs)	2014-03-19
ES2384708T3 (es)	2012-07-11
AU2007200958B2 (en)	2010-10-07
JP5036947B2 (ja)	2012-09-26
JP2014129423A (ja)	2014-07-10
HUP1300386A2 (en)	2003-10-28
IL152777A (en)	2008-11-26
PT1289992E (pt)	2006-07-31
CN1247583C (zh)	2006-03-29
BR0111328A (pt)	2003-06-10
SI1493745T1 (sl)	2012-08-31
ATE555115T1 (de)	2012-05-15
BG111017A (bg)	2011-12-30
HU230471B1 (hu)	2016-07-28
RU2005127356A (ru)	2007-03-10
EP2292622A1 (fr)	2011-03-09
MY140674A (en)	2010-01-15
IL202582A0 (en)	2010-06-30
SI1289992T1 (sl)	2006-08-31
HK1052347A1 (en)	2003-09-11
US20030181469A1 (en)	2003-09-25
SG135965A1 (en)	2007-10-29
JP2012149093A (ja)	2012-08-09
PL359172A1 (en)	2004-08-23
KR100781864B1 (ko)	2007-12-05
GB0013407D0 (en)	2000-07-26
BG110440A (bg)	2010-03-31
IS6623A (is)	2002-11-15
RU2418802C2 (ru)	2011-05-20
CZ20120293A3 (fr)	2003-07-16
EP1493745A1 (fr)	2005-01-05
AU2010257449B2 (en)	2012-03-22
AU2010257449A1 (en)	2011-01-20
ES2259031T3 (es)	2006-09-16
PL392882A1 (pl)	2011-03-14
US20070293513A1 (en)	2007-12-20
EE05222B1 (et)	2009-10-15
ATE320430T1 (de)	2006-04-15
CZ307468B6 (cs)	2018-09-26
HK1073101A1 (en)	2005-09-23
EP1289992A1 (fr)	2003-03-12
AU2001262874B2 (en)	2007-03-22
CN1432018A (zh)	2003-07-23
BG66332B1 (bg)	2013-06-28
HUP0302284A2 (hu)	2003-10-28
CN1817883A (zh)	2006-08-16
JP2003535092A (ja)	2003-11-25
BG65837B1 (bg)	2010-02-26
NO20120595L (no)	2003-01-24
NO20025756D0 (no)	2002-11-29
AU6287401A (en)	2001-12-11
NO20025756L (no)	2003-01-24
ZA200209324B (en)	2004-02-16
MY148652A (en)	2013-05-15
NO332306B1 (no)	2012-08-20
EP1493745B2 (fr)	2021-05-19
BG107331A (bg)	2003-07-31
EE200200665A (et)	2004-06-15
SK16852002A3 (sk)	2003-08-05
CY1113047T1 (el)	2016-04-13
CN1817883B (zh)	2011-10-05
AR068086A2 (es)	2009-11-04
NO20071547L (no)	2003-01-24
SK287817B6 (sk)	2011-11-04
IS2609B (is)	2010-04-15
IL152777A0 (en)	2003-06-24
DK1493745T3 (da)	2012-07-16
IS3019B (is)	2020-02-15
HUP0302284A3 (en)	2007-05-29
PT1493745E (pt)	2012-06-28
CA2408596C (fr)	2010-12-21
DE60117972D1 (de)	2006-05-11
HK1052347B (zh)	2006-09-08
MXPA02011795A (es)	2003-04-10
PH12011000127A1 (en)	2016-08-31
KR20030007829A (ko)	2003-01-23
JP5684192B2 (ja)	2015-03-11
DK1289992T3 (da)	2006-07-03
HU229374B1 (en)	2013-11-28
UA73181C2 (en)	2005-06-15
RU2010150799A (ru)	2012-06-20
IL187482A (en)	2010-06-16

Legal Events

Date	Code	Title	Description
2021-06-07	MK1K	Patent expired

Publication	Publication Date	Title
NO323780B1 (no)	2007-07-02	Nye krystallinske former av en triazolo(4,5-D)pyrimidinforbindelse, fremgangsmate for fremstilling og anvendelser av slike samt farmasoytisk preparat inneholdende nevnte nye forbindelser.
AU2001262874A1 (en)	2002-02-28	New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound
TWI330082B (en)	2010-09-11	Crystalline form of triazolo(4,5-d)pyrimidine compound and method of preparing the same
TW201034672A (en)	2010-10-01	Mixture of crystalline forms of triazolo (4,5-D) pyrimidine compound